Skip to main content
Premium Trial:

Request an Annual Quote

Microarray Analysts Should Do Their Homework


Genome Technology from August 2003 contains two articles questioning the reliability of microarray results: “Guidelines on the Way?” p. 45 and “Cross Platform,” p. 46. In “Guidelines on the Way?” the FDA dives into the messy world of microarray data and tries to come to conclusions from millions of data. In “Cross Platform” Andy Brooks says, “Lab-to-lab variation is the greatest source of error.”

Why does microarray technology not follow the principles of analytical chemistry, established about 100 years ago? Two samples should be sent to labs, these labs should do analysis of differential gene expression, results should be collected and analyzed for comparability. Then we would know about variability of results, and we could implement QC, QM, accrediting, certification, norm-administration, standard work practices, performance testing, and rule-cards. Laboratories successfully participating in performance testing would be certified to do reliable analysis; all others would have to improve. If microarray technology would do its homework, it could become a quantitative analysis method.

I believe Genome Technology would be a perfect place to start a discussion about how to get reliable results from microarray experiments.

Herbert Auer
Director of the Microarray Unit
OSU Comprehensive Cancer Center

Pay for Professors?

You omitted results for salaries from academic positions in your August issue covering the salary survey responses. Our salaries are significantly lower than any figure you published in your article. Unemployed life scientists who may be applying to academic research positions should definitely be made aware of the huge discrepancy between life in the private commercial sector and life in the public academic sector. I’ve been receiving résumés for our job openings; applicants (without a background in academia) just have no clue about the realities of salaries in academic research positions.

Jennifer Steinbachs, PhD
Deputy Director, The Center for Genomics and Bioinformatics
Indiana University

I read the article “Who’s in the Genome Money” (August 2003) with interest. I have a question about the reporting, however. In the methodology section, you describe the various organizational segments reached by the survey including pharmaceutical/ biotechnology (38 percent of respondents), university (28 percent), government (nine percent), other (25 percent). The graphs on the following pages are titled “Median salaries in pharma and biotech by organization size.” Do these three graphs include only the 38 percent of total respondents from this category as the title states? Or are all survey respondents included? If the former, will you be reporting the breakdowns for the other sectors?

Debra Kattler

Editor’s note: Salaries of academics were left out of the August cover story due to an editing oversight. See the table on p. 17 of this issue for the data. — AB


In GT’s September issue interview with Agilent’s Chris van Ingen, the number of microarray chips that the company has sold was misstated. The company sold 20,000 chips in the last quarter and 200 scanners in the last two years.


The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.